To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.

On 2026-06-30, Rep. Luttrell (R-TX-8) introduced HR9559, the psychedelic drug access and development bill. The bill has been referred to the Committees on Energy and Commerce, Judiciary, and Veterans' Affairs. As an early-stage bill with no text released and no cosponsors beyond the initial three, the legislative path is unclear. The bill does not authorize or appropriate any specific funding; it is a policy vehicle that would likely require subsequent appropriations to have financial impact. Without detailed bill text, the specific mechanisms—whether rescheduling, FDA guidance, or grant programs—are unknown. The primary affected sector is Healthcare, particularly companies involved in psychedelic drug development, but the early stage prevents drawing a direct causal chain to any specific publicly traded company. No convergence signals are present. Near-term market impact is negligible; investors should monitor committee assignments and markup sessions for clues to the bill's viability.